As expected, investors are enthused about shares of BioMimetic Therapeutics after the company took the next step in getting its Augment bone graft treatment approved by Food and Drug Administration officials. But the pop in Monday's after-hours trading was only a tease: The stock (Ticker: BMTI) is up more than 20 percent on massive volume.